Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update

Vigil Neuroscience, Inc. (NASDAQ:VIGL) was the recipient of a significant decline in short interest in the month of July. As of July 31st, there was short interest totalling 884,100 shares, a decline of 20.4% from the July 15th total of 1,110,000 shares. Approximately 5.2% of the shares of the company are short sold. Based on an average daily volume of 563,800 shares, the days-to-cover ratio is presently 1.6 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Vigil Neuroscience by 11.9% in the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock valued at $3,050,000 after buying an additional 95,276 shares in the last quarter. Ensign Peak Advisors Inc raised its position in Vigil Neuroscience by 72.8% during the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after acquiring an additional 166,442 shares during the period. Renaissance Technologies LLC lifted its holdings in Vigil Neuroscience by 19.2% during the second quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock valued at $286,000 after purchasing an additional 11,536 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Vigil Neuroscience in the second quarter valued at about $87,000. Finally, Strs Ohio purchased a new stake in shares of Vigil Neuroscience during the fourth quarter worth about $27,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Vigil Neuroscience Stock Up 18.5 %

Shares of NASDAQ VIGL traded up $0.54 during midday trading on Thursday, reaching $3.46. 270,334 shares of the stock were exchanged, compared to its average volume of 289,912. The firm has a 50-day simple moving average of $4.02 and a two-hundred day simple moving average of $3.44. Vigil Neuroscience has a twelve month low of $2.47 and a twelve month high of $9.24. The firm has a market cap of $130.04 million, a price-to-earnings ratio of -1.63 and a beta of 2.00.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on VIGL shares. HC Wainwright reissued a “buy” rating and set a $17.00 price target on shares of Vigil Neuroscience in a research report on Wednesday. Guggenheim cut their price objective on shares of Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Wednesday. JMP Securities restated a “market outperform” rating and set a $23.00 target price on shares of Vigil Neuroscience in a research report on Thursday, April 18th. Finally, Wedbush reaffirmed an “outperform” rating and set a $23.00 price target on shares of Vigil Neuroscience in a research report on Thursday, July 11th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Vigil Neuroscience has a consensus rating of “Moderate Buy” and an average target price of $16.60.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.